XML 46 R15.htm IDEA: XBRL DOCUMENT v3.20.1
NOTE 11 - SEGMENT INFORMATION
9 Months Ended
Jan. 31, 2019
Notes  
NOTE 11 - SEGMENT INFORMATION

 

NOTE 11 - SEGMENT INFORMATION

The following information is presented in accordance with ASC Topic 280, "Segment Reporting", for the three and nine months ended January 31, 2020 and 2019; we accounted for two reportable business segments - (1) natural sweetener (stevioside), and (2) corporate and other pharmaceutical. Our reportable segments are strategic business units that offer different products and are managed separately based on the fundamental differences in their operations. Condensed financial information with respect to these reportable business segments for the three and nine months ended January 31, 2020 and 2019 is as follows: 

 

 

 

Three Months Ended January 31,

Nine Months Ended January 31,

  

2020

2019

2020

2019

Revenues:

 

 

 

 

Stevioside - third parties

   $    3,320,723

       3,944,899

      12,617,001

         10,254,028

Stevioside - related parties

          1,784,135

       1,081,378

         5,882,694

           3,195,115

Total Stevioside

          5,104,858

       5,026,277

      18,499,695

         13,449,143

 

Corporate and other – third party

               98,571

           622,411

            755,390

           2,082,405

Corporate and other – related party

                          0

                       0

                         0

                           0

Total Corporate and other

               98,571

           622,411

            755,390

           2,082,405

Total segment and consolidated revenues

   $    5,203,429

       5,648,688

      19,255,085

         15,531,548

Interest (expense) income:

 

 

 

 

Stevioside

  $       (240,684)

  $      (207,474)

   $       (541,862)

  $       (589,969)

Corporate and other

                          0 

                         0 

                          0 

                         0 

Total segment and consolidated interest expense

  $       (240,684)

  $      (207,474)

   $       (541,862)

  $       (589,969)

Depreciation and amortization:

Stevioside

  $         275,906 

  $        290,386 

   $         763,429 

  $         824,360 

Corporate and other

                57,433 

                         0 

              138,255 

                         0 

Total segment and consolidated depreciation and amortization

  $         333,339 

  $        290,386 

   $         901,684 

  $         824,360 

Income (loss) before income taxes:

Stevioside

  $   (1,273,854)

  $   (1,056,344)

   $   (1,235,259)

  $   (2,558,358)

Corporate and other

                91,982 

               43,493 

              115,474 

           (633,366)

Total consolidated loss before income taxes

  $   (1,181,872)

  $   (1,012,851)

   $   (1,119,785)

  $   (3,191,724)

  

January 31, 2020

April 30, 2019

Segment property and equipment:

  Stevioside

   $     7,692,613

   $  7,796,314

  Corporate and other

          1,495,856

       1,197,083

    Total property and equipment

   $     9,188,469

   $  8,993,397